Clinical Trials Browser

Phase 2 × Melanoma × tremelimumab × Clear all

NCT00378482 2024-08-22

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Phase 2 Completed

37 enrolled 13 charts

DermatologicGastrointestinalGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT00471887 2020-10-26

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

Phase 2 Completed

32 enrolled 15 charts

Melanoma

NCT00610857 2017-06-22

Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma

Phase 2 Completed

37 enrolled 8 charts

Melanoma

NCT00254579 2012-06-07

Study of CP-675,206 in Refractory Melanoma

Phase 2 Completed

Melanoma

NCT00086489 2012-06-06

CP-675,206 In Patients With Advanced Melanoma

Phase 2 Completed

Melanoma